![Paige Mahaney](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 394 791 $ al 30/09/2026
Paige Mahaney is currently Chief Scientific Officer at C4 Therapeutics, Inc. Formerly, Dr. Mahaney was Senior VP & Corporate Head-Drug Discovery at Exelixis, Inc. Dr. Mahaney earned a doctorate from Massachusetts Institute of Technology and completed undergraduate studies at Guilford College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 14/02/2026 | 118.556 ( 0,1 % ) | 394 791 $ | 30/09/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 28/10/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| EXELIXIS, INC. | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Exelixis, Inc.
 Exelixis, Inc. Pharmaceuticals: MajorHealth Technology Operates as a cancer drug discovery company | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Guilford College
 Guilford College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
